Alzrigat, M., Párraga, A. A., Majumder, M. M., Ma, A., Jin, J., Österborg, A., . . . Jernberg-Wiklund, H. (2017). The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget.
Stile di citazione ChicagoAlzrigat, Mohammad, et al. "The Polycomb Group Protein BMI-1 Inhibitor PTC-209 Is a Potent Anti-myeloma Agent Alone or in Combination With Epigenetic Inhibitors Targeting EZH2 and the BET Bromodomains." Oncotarget 2017.
Citazione MLAAlzrigat, Mohammad, et al. "The Polycomb Group Protein BMI-1 Inhibitor PTC-209 Is a Potent Anti-myeloma Agent Alone or in Combination With Epigenetic Inhibitors Targeting EZH2 and the BET Bromodomains." Oncotarget 2017.